Pharma Focus Asia
KP - Choose our fully recyclable blister films

Novel APL-106 (uproleselan) Discovered for the Treatment of Acute Myeloid Leukemia

Apollomics, Inc discovered novel APL-106 (uproleselan) for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) in China.

AML is an aggressive disease and relapsed/refractory having an extremely poor prognosis in patients.

AML is a blood and bone marrow cancer. It is an aggressive disease which causes the bone marrow to produce immature cells which cannot carry out their normal function and thus results in developing into leukemic white blood cells called myeloblasts. In addition, every year 20,000 new cases of AML generate.

(APL-106) is a late clinical stage first-in-class, targeted inhibitor of E-selectin. In September 2020, the NMPA CDE has granted Investigational New Drug (IND) approval for APL-106 enabling the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML

APL-106 (uproleselan) has been granted Breakthrough Therapy Designation for the treatment of Acute Myeloid Leukemia in China.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024